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Abstract: Coordinated unfolding of innate and adaptive immunity is key to the development of protective immune 
responses. This functional integration occurs within the inflamed tissue, a microenvironment enriched with factors 
released by innate and subsequently adaptive immune cells and the injured tissue itself. T lymphocytes are key play-
ers in the ensuing adaptive immunity and their proper function is instrumental to a successful outcome of immune 
protection. The site of inflammation is a “harsh” environment in which T cells are exposed to numerous factors that 
might influence their behavior. Low pH and oxygen concentration, high lactate and organic acid content as well as 
free fatty acids and reactive oxygen species are found in the inflammatory microenvironment. All these components 
affect T cells as well as other immune cells during the immune response and impact on the development of chronic 
inflammation. We here overview the effects of a number of factors present in the inflammatory microenvironment 
on T cell function and migration and discuss the potential relevance of these components as targets for therapeutic 
intervention in autoimmune and chronic inflammatory diseases.
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Introduction
In multicellular organisms inflammation is a 
characteristic reaction of the immune system 
to extrinsic or intrinsic danger stimuli that 
favors the reestablishment of tissue homeosta-
sis. Acute inflammation on one hand is trig-
gered by infection, tissue injury or malfunction 
and describes the short-term recruitment of 
immune cells into the affected site whose phys-
iological purpose is pathogen clearance and 
tissue repair. Chronic inflammation on the other 
hand is a low-grade, constant and long-lasting 
tissue infiltration of immune cells, which often 
causes severe tissue damage and remodeling, 
a common feature of autoimmune and chronic 
inflammatory diseases, such as atherosclero-
sis, rheumatoid arthritis and diabetes [1].
T lymphocytes play a major role in the develop-
ment of these inflammatory processes. Besides 
their direct cytotoxic activities, T cells orches-
trate the unfolding immune response via the 
secretion of pro- and anti-inflammatory cyto-
kines that influence the severity and outcome 
of the inflammatory reaction [2]. Both effector 
and regulatory T (Treg) cells are essential to 
establish and maintain an effective immune 
response or dampen an overshooting reaction 
to prevent autoimmune disease. Therefore, the 
resolution of the inflammatory process follow-
ing pathogen clearance depends on the con-
certed localization of both these T cell subsets 
to reach an optimal ratio, which terminates 
effector immunity [3]. Several well-described 
stimuli direct the function and migration pat-
terns of T lymphocytes, such as cytokines, che-
mo-attractants and -repellents or direct cell-cell 
interactions [4, 5].
In this context, some of the components of the 
inflammatory microenvironment are likely to 
impact on the dynamic progression of the 
inflammatory process. Low glucose, nutrient 
and oxygen concentration, high lactate and 
organic acid content, the presence of fatty 
acids and other metabolites make the inflam-
matory site a unique “milieu” that affects 
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immune cells in a yet underappreciated man-
ner. Substantial evidence for the metabolic 
control of T cell function and their response to 
environmental changes has recently emerged. 
The discovery that T cell subsets rely upon dif-
ferent energy sources and respond to diverse 
signaling cues opens up novel ways of thera-
peutically interfering with immune cell function 
in chronic inflammatory disorders [6-11].
This review focuses on the effect of some of the 
essential factors present in the inflammatory 
microenvironment, including oxygen concentra-
tion, pH, fatty acids, lactate and reactive oxy-
gen species (ROS), on immune cell function, 
particularly that of T cells, within the inflamma-
tory site.
Components of the inflammatory “milieu”
The inflammatory site is a hostile and harsh 
environment for T cells to function and suc-
cessfully fulfill their tasks. Although its molecu-
lar composition slightly differs from disease to 
disease, some similarities exist that could be 
considered for effective therapeutic targeting.
The effect on T cells of some of the factors 
present in the inflammatory microenvironment, 
particularly those commonly present in chronic 
inflammation, including oxygen concentration, 
pH, lactate, fatty acids and ROS will be dis-
cussed (Figure 1).
As the role of cytokines, chemokines and dan-
ger-associated molecular patterns (DAMPs) as 
major signaling molecules that regulate T cell 
function and correct tissue localization during 
an immune response has been extensively 
examined in recent excellent articles [12-15], 
we will not discuss their role in detail.
Hypoxia defines the inflammatory environ-
ment
Inflamed tissues are often characterized by 
decreased oxygen availability (<2%) [16], gener-
ally known as hypoxia. Inflammation-associated 
tissue hypoxia is due to an imbalance in oxygen 
demand and supply in inflammatory sites. On 
one hand hypoxia is a consequence of 
increased oxygen consumption by resident 
cells such as epithelia or vascular endothelia, 
Figure 1. Factors in the inflammatory microenvironment. Several factors in the inflammatory microenvironment 
(e.g., oxygen concentration, pH, lactate, fatty acids and ROS) can influence the function of T cells and other immune 
cells on a number of levels and determine the outcomes of the inflammatory process.
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and also by recruited inflammatory cells, such 
as macrophages, neutrophils and T cells [17], 
which are metabolically extremely active. On 
the other hand oxygen supply in the inflamma-
tory site is often decreased due to vascular 
occlusion or thrombosis [18]. Furthermore, not 
only inflamed tissues often become hypoxic, 
but hypoxia promotes inflammation due to the 
increased release of inflammatory cytokines by 
the hypoxic tissue and subsequent recruitment 
of inflammatory cells. Therefore, inflammation 
and hypoxia are intertwined in a forward feed-
back loop that is key to the establishment of 
chronic inflammation [18].
In diabetes and obesity oxygen consumption 
rises due to the increase of adipose mass. As a 
consequence, the adipose tissue becomes 
hypoxic. A study showed that both wild type 
mice on high fat diet and leptin-deficient (ob/
ob) mice have a decreased partial oxygen pres-
sure in their white adipose tissue [19]. In the 
hypoxic environment adipocytes increase the 
expression of the pro-inflammatory cytokines 
TNFα, IL-1, IL-6 and TGFβ and the chemokine 
MIF, which in turn are responsible for macro-
phage and T cell recruitment [19]. Furthermore, 
the expression of the extracellular enzyme 
matrix metalloproteinase-9 (MMP-9) is elevat-
ed during hypoxia and this has been shown to 
correlate with early neutrophil infiltration in the 
inflammatory site [20]. In a recent study, 
Fujisaka et al. demonstrated that hypoxia in the 
adipose tissue is responsible for the induction 
of inflammatory M1 polarity of macrophages in 
a HIF1α-dependent and -independent manner 
[21].
As the above-mentioned studies show, hypoxia 
and inflammation are tightly interconnected 
and tissue hypoxia can be found in a variety of 
other chronic inflammatory diseases. Athe- 
rosclerosis [22], rheumatoid arthritis [23], 
inflammatory bowel disease [24], sepsis [25], 
ischemic stroke [26] and fast growing tumors 
[27] have all been associated with severe short-
age of oxygen in the inflamed tissues. Cells 
exposed to an environment with low oxygen 
concentration up-regulate several survival 
mechanisms, which are under the control of 
the oxygen sensitive transcription factor, HIF1α. 
Under normoxic conditions (2-3%) [16], HIF1α is 
hydroxylated by prolyl-hydroxy-domain contain-
ing enzymes (PHDs), which target HIF1α for 
ubiquitinylation-dependent degradation by the 
proteasome. However, hypoxia-induced inacti-
vation of PHDs triggers HIF1α translocation to 
the nucleus where it promotes the transcription 
of up to 200 target genes. Many of these genes 
are important for cell survival [28]. Nevertheless, 
despite the activation of survival pathways, 
some highly proliferative cells, such as T lym-
phocytes, cannot cope with the depletion of 
oxygen. In a recent study, Gaber and colleagues 
observed that CD4+ T cells have a reduced rate 
of proliferation and survival in a model of phyto-
hemagglutinin-stimulated T cell growth in 
hypoxic conditions [16].
In addition to the induction of obvious survival 
pathways in hypoxic environments, CD4+ T cells 
simultaneously decrease cytokine production. 
This decline in T cell effector function has been 
proposed to be a protective mechanism against 
prolonged tissue damage caused by hyper 
reactive T cells in inflammatory conditions [29]. 
However, the lytic function of cytotoxic CD8+ T 
lymphocytes (CTLs) has been shown to be unaf-
fected or even enhanced by low oxygen pres-
sure [30].
In conclusion, oxygen levels in inflamed tissues 
are generally lower than in healthy tissues, 
making hypoxia a main feature of the inflamma-
tory microenvironment and an important factor 
in the development and progression of inflam- 
mation.
Low pH inhibits cellular function
The effect of intra- and extracellular pH varia-
tions on cell function has long been recognized. 
A decrease in pH generally inhibits most cellu-
lar functions including enzyme activities, ion 
transport, DNA and protein synthesis, and influ-
ences cAMP and calcium levels [31]. The inflam-
matory microenvironment is characterized by a 
decrease in pH. Measurements of pH in the 
synovial fluid of healthy (7.768±0.044), trau-
matic (7.559±0.031) or osteoarthritic (7.549± 
0.040) patients, for instance, showed a 
decrease of about 0.2 pH units in an array of 
patients [32]. An even steeper decrease of pH 
was found in atherosclerotic plaques in humans 
(7.15) [33]. The tumor environment can have 
pH values below 6, which has been suggested 
to contribute to the establishment of immune 
escape mechanisms [31].
The low pH in inflamed tissues often originates 
from increased metabolism of parenchymal 
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and recruited inflammatory cells in conjunction 
with decreased oxygen availability [31]. Most 
cells rely upon oxidative phosphorylation for 
ATP production in the presence of oxygen. 
During hypoxia, cells switch their energy metab-
olism to anaerobic glycolysis, which leads to 
increased production of lactate. Increased lac-
tate in turn is coupled, even if only indirectly, 
with the secretion of protons that causes a 
drop in pH [34].
Although most studies that focus on the effect 
of extracellular pH on cell function show gener-
ally a decrease, different effects can occur in 
distinct cell types. Trevani et al. showed that 
lowering the extracellular pH to 6.5 enhances 
the activation of neutrophils, which might lead 
to an intensification of the innate immune 
response [35]. The acidic pH causes an intra-
cellular accumulation of calcium that leads to 
an elevated production of H2O2 [35]. Another 
group has shown that acidic pH drives activa-
tion of integrin αvβ3, a receptor for vitronectin 
[36]. This increase in integrin affinity and avidi-
ty leads to a strengthening of cell-cell connec-
tions, which in turn slows down the migration of 
neutrophils [37]. Unlike neutrophils, T cells 
exposed to low pH display a decrease in their 
immune function. As reported by Redegeld et 
al., cytotoxic T lymphocytes lose their lytic func-
tion in a low pH environment [38]. Furthermore, 
it is known that low pH causes reduced interac-
tions of lymphocytes with the extracellular 
matrix, which in turn leads to reduced migra-
tion. The specific molecular mechanisms of 
these pH-afforded effects on lymphocytes 
migration, however, remain elusive [31].
To sum up, low pH is commonly found in the 
inflammatory microenvironment and affects 
the migration and effector function of lympho-
cytes and other immune cells, thereby contrib-
uting to the progression of the inflammatory 
process.
‘Fat’ signals
The presence of free fatty acids (FFAs) in the 
inflammatory environment is yet to be proven to 
be a general occurrence. In obesity though, 
free fatty acids are abundant in the fat mass 
due to the fat breakdown in mature adipocytes 
[39]. As obesity is a major risk factor for athero-
sclerosis, FFAs have also been found to be 
highly enriched in the arterial walls [40]. 
Together with cholesterol, FFAs are the forerun-
ners of plaque formation, as they accumulate 
at the level of the arterial wall and trigger resi-
dent macrophages to become foam cells [41].
In addition to macrophages, it is becoming 
increasingly evident that T cells are recruited in 
the very early stages of atherosclerotic plaque 
formation and play a major role in the inflam-
matory process driving the development of ath-
erosclerosis [40]. CD4+ TH1 cells are responsible 
for the amplification of the local immune 
response in atherosclerotic plaques via the 
secretion of the pro-inflammatory cytokines 
INFγ, IL-2 and IL-3 as well as TNFα and β [42]. 
CD4+ T cells have also been shown to polarize 
to a TH1 phenotype with increased IFNγ expres-
sion in obese children [43].
Considering the crucial role of T cells in the 
pathogenesis of lipid-enriched inflammatory 
diseases, it is important to understand the pos-
sible effects that lipids might exert on T cell 
function. Based on the geometry of the double 
bond, unsaturated fatty acids exist in two iso-
forms: cis-isomers and trans-isomers. In cis-
isomers, adjacent hydrogen atoms are on the 
same side of the double bond, whereas in 
trans-isomers adjacent hydrogen atoms are on 
opposite sides of the double bond. With cis-
isomers the rigidity of the double bond freezes 
their conformation and causes the chain to 
bend and restricts the conformational freedom 
of the fatty acid. In trans-isomers, instead, dou-
ble bonds are more flexible, therefore they do 
not cause the chain to bend much and their 
shape is similar to straight saturated fatty 
acids. These two isoforms have different 
effects on T cells. Stulnig et al. reported 
decreased calcium-signaling responses in cul-
tured Jurkat T cells, when treated with long 
chain cis-unsaturated FFAs. In contrast, trans-
unsaturated or saturated FFAs had no effect. 
Moreover, they observed that primary T cells 
isolated from blood of patients given an elevat-
ed dose of cis-unsaturated FFAs also showed 
diminished calcium signaling after in-vitro acti-
vation [44].
Zeyda et al. went on to identify the specific 
steps of the TCR downstream signaling path-
way that are affected by polyunsaturated fatty 
acids (PUFAs) [45]. A selective inhibition of 
mitogen activated protein kinase (MAPK), Janus 
Kinase (JNK), was observed, with no effect on 
other MAP kinases. Although JNK was inhibit-
ed, they were unable to detect any change in 
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AP-1 (c-JUN) activity, the main downstream 
transcription factor of JNK. They found instead 
a selective inhibition of NF-AT transcription fac-
tor, which is possibly due to diminished calcium 
signaling. As NF-AT activates IL-2 transcription 
[46], the observed decrease in IL-2 expression 
upon PUFAs treatment was somehow expect-
ed. Notably, also the TH2 type cytokine IL-13 was 
suppressed by the same treatment, suggesting 
an additional mechanism of action of PUFAs 
downstream of TCR [45].
Geyeregger et al. demonstrated yet another 
mechanism of PUFAs action in T cells following 
activation with the superantigen (SAg) staphy-
lococcus enterotoxin E. Herein, the SAg induc-
es a non-specific T cell activation by peptide-
independent ligation of MHC molecules with 
the TCR that results in polyclonal T cell expan-
sion and massive cytokine release. In this 
model, the formation of the immunological syn-
apse was inhibited following treatment with the 
n-3 PUFA, eicosapentaenoic acid (EPA). Upon 
EPA treatment, cytoskeletal rearrangements, 
necessary for the formation of the synapse 
were blunted, probably due to reduced Vav-
phosphorylation [47], which acts as a promoter 
of the synapse formation via linking the actin 
cytoskeleton to TCR signaling [48].
Furthermore, the n-3 PUFAs, EPA and docosa-
hexaenoic acid (DHA), were shown to affect T 
cell migration and expression of MMP-9 in 
Jurkat T cells. Both EPA and DHA significantly 
decreased the migration of T cells and reduced 
activity of the enzyme MMP-9, which has been 
associated with the disruption of the blood 
brain barrier and subsequent invasion of the 
central nervous system by inflammatory cells. 
Authors of this study proposed a possible treat-
ment for patients with multiple sclerosis, 
whereby EPA / DHA supplied exogenously could 
benefit the disease prognosis [49]. In athero-
sclerosis or rheumatoid arthritis instead enrich-
ment of n-3 PUFAs in the inflamed tissues could 
potentially be harmful due to the inhibition of 
the migratory capacity of inflammatory cells 
which would become unable to leave the inflam-
matory site timely, thereby favoring the devel-
opment of the disease into a chronic state.
Lactate, a multi-faceted signaling molecule
The short chain monocarboxylate lactate has a 
long history in biochemistry, reaching from the 
first description of lactic acid in sour milk in 
1780 and the presence in human blood in 
1843 [50], to the discovery of lactate produc-
tion by highly proliferative tumor cells [51] and 
the finding that lactate was enriched in several 
inflammatory diseases and the tumor microen-
vironment [52]. Generally, lactate is considered 
a metabolic ‘waste product’ and the result of 
high glycolytic activity in proliferating cells. This 
view on lactate has been changing consider-
ably in recent times, as its role as an important 
signaling molecule is being recognized [53].
In the brain, lactate acts as a fuel source for 
oxidative energy metabolism in neurons. 
Thereby, high glutamate levels increase the gly-
colytic activity of specific glial cells known as 
astrocytes, which in turn produce lactate and 
transport it into neurons, which use it as an 
additional energy source [54]. Besides neu-
rons, lactate has significant effects on other 
cell types as well. The migration potential of 
tumor cells, for instance, increases in the pres-
ence of lactate [55]. Furthermore, Baumann et 
al. showed that glioma cell migration is 
enhanced, as lactate induces a TGF-β2-
dependent regulation of matrix metallopepti-
dase 2 (MMP-2) [56]. These findings could have 
important implications in the understanding of 
tumor progression and metastasis formation.
Lactate indirectly stimulates the migration of 
endothelial cells via enhanced VEGF secretion, 
which is a potential promoter of wound healing 
[57]. This effect is possibly explained by the 
uptake of extracellular lactate by endothelial 
cells [58] and the stimulation of HIF1α up-regu-
lation [59], which has been shown to correlate 
with increased VEGF secretion [60].
Most importantly, lactate is locally enriched in 
inflamed tissues, such as the joints in rheuma-
toid arthritis, atherosclerotic plaques and 
tumors [52, 61, 62]. Moreover, elevated lactate 
levels in the blood have been associated with 
increased prevalence of atherosclerosis and 
type II diabetes [63]. Fischer et al. showed that 
human cytotoxic T cells are able to take up lac-
tate and thereupon are inhibited in their prolif-
eration potential. This effect was only observed 
in the presence of elevated H+ ions, or low pH 
[64]. It is tempting to speculate that T cells 
entering the inflammatory site become exposed 
to elevated levels of lactate, between 10 and 
30 mM, which disables their ability to emigrate 
and favor their retention. If proven correct, this 
hypothesis could provide an additional mecha-
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nism to explain the issue of non-resolving 
inflammation and its progression to a chronic 
process [65, 66].
As the above-mentioned studies demonstrate, 
lactate is a multi-faceted signaling molecule 
and its effects on cell function are likely to be 
more far-reaching than understood at present.
Reactive oxygen species
The effects of reactive oxigen species (ROS) on 
cells have historically been associated with 
physiological dysfunction and cellular damage. 
This view is about to be extended by recent 
findings suggesting roles for ROS in intracellu-
lar signaling events, induction of apoptotic 
pathways, cell activation and feedback mecha-
nisms to metabolism [67]. Increased ROS pro-
duction has been associated with a wide vari-
ety of diseases, including neurodegenerative 
disorders, diabetes, cancer and atherosclero-
sis [68-70]. ROS, such as superoxide (O2
-), can 
be generated from several sources, which 
include NADPH oxidase (NOX), xanthine oxi-
dase (XO), nitric oxide synthase (NOS), cyto-
chrome P450 and the mitochondrial electron 
transport chain (ETC) [71]. Most ROS are gener-
ated via the electron reduction of the oxygen 
molecule, O2, during oxidative phosphorylation 
in the mitochondria. Superoxide is then trans-
pens during the respiratory burst of neutro-
phils, also phagocytes have the ability to pro-
duce and release superoxide by using a plasma 
membrane bound NADPH oxidase [75].
Although superoxide cannot permeate the 
membrane due to its negative charge, the main 
product of the superoxide dismutase, H2O2, is 
permeable and might contribute to the majority 
of the signaling function of ROS [76]. It has 
recently been shown that ROS production in 
mitochondria is required for the induction of 
NF-AT and subsequent IL-2 production in acti-
vated T cells [77]. In addition, it has been 
reported that redox signaling via H2O2 could 
alter the proteome of activated T cells both in a 
qualitative and quantitative manner, thereby 
directly affecting the function of T cells in 
inflammation [78]. Therefore, H2O2 appears to 
be an important factor in the inflammatory envi-
ronment in which it affects immune cells acti-
vation and function.
Conclusions
In this review we describe a number of compo-
nents of the inflammatory microenvironment 
that can have critical effects on the function of 
the immune cells recruited to the site of inflam-
mation and might have an impact on the pro-
gression of inflammation into a chronic condi-
Figure 2. Effects of factors present in the inflammatory microenvironment 
on the establishment of chronic inflammation. Not only inflammation in-
ducing signals (e.g., cytokines, chemokines, DAMPs) lead to the recruit-
ment of immune cells to the site of inflammation. Additionally factors within 
the inflammatory microenvironment (depicted in Figure 1) affect the be-
havior of immune cells in terms of recruitment, retention and function, and 
contribute to the establishment of chronic inflammation.
formed into H2O2 by superoxide 
dismutase to prevent ROS from 
causing intracellular damage to 
the cell [67]. It is thought that 
0.2-2% of the oxygen con-
sumed from mitochondria is 
transformed to superoxide 
[72]. This mitochondrial ROS 
can have several effects on the 
cell, including induction of 
autophagy under starving con-
ditions [73], regulation of dif-
ferentiation and promotion of 
aging [74].
As most ROS are produced in 
the mitochondria, they exert 
their damaging function mainly 
inside the cell. ROS are never-
theless abundantly present in 
the sites of inflammation and 
thus affect immune cells in 
their function. Besides the 
superoxide release that hap-
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tion. With regard to T lymphocytes, these 
factors can promote long-term accumulation of 
activated T cells in the site of inflammation due 
to the increase of both recruitment and reten-
tion mechanisms. Furthermore, these factors 
can cause functional alteration of the immune 
cells present in the inflammatory microenviron-
ment. All these aspects conceivably contribute 
to the development of chronic inflammation [1] 
(Figure 2). 
At present, most studies have focused on 
effects elicited by a single component on a 
defined cell type, however the overall land-
scape of the inflammatory process is likely to 
be dynamically and qualitatively defined by the 
effects of multiple factors on a variety of 
immune cellular components. For this reason it 
will be essential to systematically study the 
effects of these factors on immune cells 
recruited to the inflammatory sites. Not only 
should they be studied alone but also in combi-
nation, in order to establish potential synergis-
tic or neutralizing effects on the outcome of the 
inflammatory process. 
Although inflammatory microenvironments may 
differ among diseases, they all exert effects on 
the recruited immune cells leading to the per-
sistence of the inflammatory process. 
Therefore, an accurate description of inflamma-
tory elements and comparison in different 
pathologies is of crucial importance. This would 
enable a better understanding of the inflamma-
tory process leading to the development of 
chronic disease, and open up a variety of novel 
therapeutic interaction possibilities.
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